The DOI matches its Crossref record; 259 of the 259 references it cites were found in a registry or an index.
CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4
Open accessAbstract
CC chemokines, a subfamily of 27 chemotactic cytokines, are a component of intercellular communication, which is crucial for the functioning of the tumor microenvironment. Although many individual chemokines have been well researched, there has been no comprehensive review presenting the role of all known human CC chemokines in the hallmarks of cancer, and this paper aims at filling this gap. The first part of this review discusses the importance of CCL1, CCL3, CCL4, CCL5, CCL18, CCL19, CCL20, CCL21, CCL25, CCL27, and CCL28 in cancer. Here, we discuss the significance of CCL2 (MCP-1), CCL7, CCL8, CCL11, CCL13, CCL14, CCL15, CCL16, CCL17, CCL22, CCL23, CCL24, and CCL26. The presentation of each chemokine includes its physiological function and then the role in tumor, including proliferation, drug resistance, migration, invasion, and organ-specific metastasis of tumor cells, as well as the effects on angiogenesis and lymphangiogenesis. We also discuss the effects of each CC chemokine on the recruitment of cancer-associated cells to the tumor niche (eosinophils, myeloid-derived suppressor cells (MDSC), tumor-associated macrophages (TAM), tumor-associated neutrophils (TAN), regulatory T cells (Treg)). On the other hand, we also present the anti-cancer properties of CC chemokines, consisting in the recruitment of tumor-infiltrating lymphocytes (TIL).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Al-Haidari, A. A., Syk, I., Jirström, K., & Thorlacius, H. (2013) · International Journal of Colorectal Disease · doi:10.1007/s00384-013-1712-y · Cited by 46
RetractedEffect of CCL2 siRNA on proliferation and apoptosis in the U251 human glioma cell line
Lu, B., Zhou, Y., Su, Z., Yan, A., & Ding, P. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6995 · Cited by 22
RetractedGuo, S., Liu, R., Wen, Y., Liu, L., Li, Y., Li, Y.-X., Li, Y., Hao, W., Peng, J., Chen, D., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.008 · Cited by 14
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Monocyte Chemoattractant Protein-1 (MCP-1): An Overview
Deshmane, S. L., Kremlev, S., Amini, S., & Sawaya, B. E. (2009) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2008.0027 · Cited by 3,889
Zlotnik, A., & Yoshie, O. (2000) · Immunity · doi:10.1016/s1074-7613(00)80165-x · Cited by 3,859
Fagerberg, L., Hallström, B. M., Oksvold, P., Kampf, C., Djureinovic, D., Odeberg, J., Habuka, M., Tahmasebpoor, S., Danielsson, A., Edlund, K., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.035600 · Cited by 3,665
A pathology atlas of the human cancer transcriptome
Uhlen, M., Zhang, C., Lee, S., Sjöstedt, E., Fagerberg, L., Bidkhori, G., Benfeitas, R., Arif, M., Liu, Z., Edfors, F., et al. (2017) · Science · doi:10.1126/science.aan2507 · Cited by 3,371
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874 · cited 1×
“This allows it to effectively recruit macrophages, which participate in the early stage of the development of a metastatic niche [134,167].”
BackgroundA guide to chemokines and their receptors
Hughes, C. E., & Nibbs, R. J. B. (2018) · The FEBS Journal · doi:10.1111/febs.14466 · Cited by 1,412
Arneth, B. (2019) · Medicina · doi:10.3390/medicina56010015 · Cited by 1,250
Boring, L., Gosling, J., Chensue, S. W., Kunkel, S. L., Farese, R. V., Broxmeyer, H. E., & Charo, I. F. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119798 · Cited by 1,096
Lu, B., Rutledge, B. J., Gu, L., Fiorillo, J., Lukacs, N. W., Kunkel, S. L., North, R., Gerard, C., & Rollins, B. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.601 · Cited by 1,017
Salcedo, R., Ponce, M. L., Young, H. A., Wasserman, K., Ward, J. M., Kleinman, H. K., Oppenheim, J. J., & Murphy, W. J. (2000) · Blood · doi:10.1182/blood.v96.1.34 · Cited by 859
Zhou, S.-L., Zhou, Z.-J., Hu, Z.-Q., Huang, X.-W., Wang, Z., Chen, E.-B., Fan, J., Cao, Y., Dai, Z., & Zhou, J. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.040 · Cited by 852
Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo
Jetten, N., Verbruggen, S., Gijbels, M. J., Post, M. J., De Winther, M. P. J., & Donners, M. M. P. C. (2014) · Angiogenesis · doi:10.1007/s10456-013-9381-6 · Cited by 839
Tumor entrained neutrophils inhibit seeding in the premetastatic lung
Granot, Z., Henke, E., Comen, E. A., King, T. A., Norton, L., & Benezra, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.012 · Cited by 782
Yang, X., Lin, Y., Shi, Y., Li, B., Liu, W., Yin, W., Dang, Y., Chu, Y., Fan, J., & He, R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2973 · Cited by 748
Ponath, P. D., Qin, S., Ringler, D. J., Clark-Lewis, I., Wang, J., Kassam, N., Smith, H., Shi, X., Gonzalo, J. A., Newman, W., et al. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118456 · Cited by 697
Kitamura, T., Qian, B.-Z., Soong, D., Cassetta, L., Noy, R., Sugano, G., Kato, Y., Li, J., & Pollard, J. W. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141836 · Cited by 651
Chang, A. L., Miska, J., Wainwright, D. A., Dey, M., Rivetta, C. V., Yu, D., Kanojia, D., Pituch, K. C., Qiao, J., Pytel, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0144 · Cited by 640
McQuibban, G. A., Gong, J.-H., Wong, J. P., Wallace, J. L., Clark-Lewis, I., & Overall, C. M. (2002) · Blood · doi:10.1182/blood.v100.4.1160.h81602001160_1160_1167 · Cited by 611
Roca, H., Varsos, Z. S., Sud, S., Craig, M. J., Ying, C., & Pienta, K. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.042671 · Cited by 569
Imai, T., Baba, M., Nishimura, M., Kakizaki, M., Takagi, S., & Yoshie, O. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.23.15036 · Cited by 555
Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G., & Colombo, M. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4262 · Cited by 549
Heath, H., Qin, S., Rao, P., Wu, L., LaRosa, G., Kassam, N., Ponath, P. D., & Mackay, C. R. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119145 · Cited by 457
Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype
Gabrusiewicz, K., Rodriguez, B., Wei, J., Hashimoto, Y., Healy, L. M., Maiti, S. N., Thomas, G., Zhou, S., Wang, Q., Elakkad, A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85841 · Cited by 445
CCR4 and its ligands: from bench to bedside
Yoshie, O., & Matsushima, K. (2015) · International Immunology · doi:10.1093/intimm/dxu079 · Cited by 427
Iannello, A., Thompson, T. W., Ardolino, M., Lowe, S. W., & Raulet, D. H. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130783 · Cited by 414
Kitaura, M., Nakajima, T., Imai, T., Harada, S., Combadiere, C., Tiffany, H. L., Murphy, P. M., & Yoshie, O. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.13.7725 · Cited by 408
Tsuyada, A., Chow, A., Wu, J., Somlo, G., Chu, P., Loera, S., Luu, T., Li, A. X., Wu, X., Ye, W., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3567 · Cited by 407
Forssmann, U., Uguccioni, M., Loetscher, P., Dahinden, C. A., Langen, H., Thelen, M., & Baggiolini, M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.12.2171 · Cited by 407
Macrophage-derived Chemokine Is a Functional Ligand for the CC Chemokine Receptor 4
Imai, T., Chantry, D., Raport, C. J., Wood, C. L., Nishimura, M., Godiska, R., Yoshie, O., & Gray, P. W. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.3.1764 · Cited by 378
Mizukami, Y., Kono, K., Kawaguchi, Y., Akaike, H., Kamimura, K., Sugai, H., & Fujii, H. (2008) · International Journal of Cancer · doi:10.1002/ijc.23392 · Cited by 374
Korbecki, J., Grochans, S., Gutowska, I., Barczak, K., & Baranowska-Bosiacka, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207619 · Cited by 373
Self-citationOgura, M., Ishida, T., Hatake, K., Taniwaki, M., Ando, K., Tobinai, K., Fujimoto, K., Yamamoto, K., Miyamoto, T., Uike, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.0924 · Cited by 362
Yamamoto, K., Utsunomiya, A., Tobinai, K., Tsukasaki, K., Uike, N., Uozumi, K., Yamaguchi, K., Yamada, Y., Hanada, S., Tamura, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3575 · Cited by 354
Flores-Toro, J. A., Luo, D., Gopinath, A., Sarkisian, M. R., Campbell, J. J., Charo, I. F., Singh, R., Schall, T. J., Datta, M., Jain, R. K., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910856117 · Cited by 334
Tumor microenvironments direct the recruitment and expansion of human Th17 cells
Su, X., Ye, J., Hsueh, E. C., Zhang, Y., Hoft, D. F., & Peng, G. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902813 · Cited by 324
Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1
Goede, V., Brogelli, L., Ziche, M., & Augustin, H. G. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990827)82:5<765::aid-ijc23>3.0.co;2-f · Cited by 319
Garcia-Zepeda, E. A., Combadiere, C., Rothenberg, M. E., Sarafi, M. N., Lavigne, F., Hamid, Q., Murphy, P. M., & Luster, A. D. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.12.5613 · Cited by 316
Breast Cancer Lung Metastasis Requires Expression of Chemokine Receptor CCR4 and Regulatory T Cells
Olkhanud, P. B., Baatar, D., Bodogai, M., Hakim, F., Gress, R., Anderson, R. L., Deng, J., Xu, M., Briest, S., & Biragyn, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4619 · Cited by 312
Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma
Kalbasi, A., Komar, C., Tooker, G. M., Liu, M., Lee, J. W., Gladney, W. L., Ben-Josef, E., & Beatty, G. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0870 · Cited by 305
CCR5 Binds Multiple CC-Chemokines: MCP-3 Acts as a Natural Antagonist
Blanpain, C., Migeotte, I., Lee, B., Vakili, J., Doranz, B. J., Govaerts, C., Vassart, G., Doms, R. W., & Parmentier, M. (1999) · Blood · doi:10.1182/blood.v94.6.1899 · Cited by 287
Sandhu, S. K., Papadopoulos, K., Fong, P. C., Patnaik, A., Messiou, C., Olmos, D., Wang, G., Tromp, B. J., Puchalski, T. A., Balkwill, F., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2099-8 · Cited by 272
Eotaxin (CCL11) Induces In Vivo Angiogenic Responses by Human CCR3+ Endothelial Cells
Salcedo, R., Young, H. A., Ponce, M. L., Ward, J. M., Kleinman, H. K., Murphy, W. J., & Oppenheim, J. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7571 · Cited by 257
Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1
Proost, P., Wuyts, A., & van Damme, J. (1996) · Journal of Leukocyte Biology · doi:10.1002/jlb.59.1.67 · Cited by 254
Mishalian, I., Bayuh, R., Eruslanov, E., Michaeli, J., Levy, L., Zolotarov, L., Singhal, S., Albelda, S. M., Granot, Z., & Fridlender, Z. G. (2014) · International Journal of Cancer · doi:10.1002/ijc.28770 · Cited by 253
Menzies-Gow, A., Ying, S., Sabroe, I., Stubbs, V. L., Soler, D., Williams, T. J., & Kay, A. B. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.5.2712 · Cited by 249
Monocyte chemoattractant protein–1 increases microglial infiltration and aggressiveness of gliomas
Platten, M., Kretz, A., Naumann, U., Aulwurm, S., Egashira, K., Isenmann, S., & Weller, M. (2003) · Annals of Neurology · doi:10.1002/ana.10679 · Cited by 249
Chiu, D. K., Xu, I. M., Lai, R. K., Tse, A. P., Wei, L. L., Koh, H., Li, L. L., Lee, D., Lo, R. C., Wong, C., et al. (2016) · Hepatology · doi:10.1002/hep.28655 · Cited by 241
Patel, V. P., Kreider, B. L., Li, Y., Li, H., Leung, K., Salcedo, T., Nardelli, B., Pippalla, V., Gentz, S., Thotakura, R., et al. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.7.1163 · Cited by 240
Duvic, M., Pinter-Brown, L. C., Foss, F. M., Sokol, L., Jorgensen, J. L., Challagundla, P., Dwyer, K. M., Zhang, X., Kurman, M. R., Ballerini, R., et al. (2015) · Blood · doi:10.1182/blood-2014-09-600924 · Cited by 230
Torres, S., Bartolomé, R. A., Mendes, M., Barderas, R., Fernandez-Aceñero, M. J., Peláez-García, A., Peña, C., Lopez-Lucendo, M., Villar-Vázquez, R., de Herreros, A. G., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1130 · Cited by 227
Li, D., Ji, H., Niu, X., Yin, L., Wang, Y., Gu, Y., Wang, J., Zhou, X., Zhang, H., & Zhang, Q. (2020) · Cancer Science · doi:10.1111/cas.14230 · Cited by 227
Liu, Q., Yang, C., Wang, S., Shi, D., Wei, C., Song, J., Lin, X., Dou, R., Bai, J., Xiang, Z., et al. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00557-2 · Cited by 226
Tripathi, C., Tewari, B. N., Kanchan, R. K., Baghel, K. S., Nautiyal, N., Shrivastava, R., Kaur, H., Bhatt, M. L. B., & Bhadauria, S. (2014) · Oncotarget · doi:10.18632/oncotarget.2110 · Cited by 224
Liu, J., Chen, S., Wang, W., Ning, B.-F., Chen, F., Shen, W., Ding, J., Chen, W., Xie, W.-F., & Zhang, X. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.05.022 · Cited by 218
Kitaura, M., Suzuki, N., Imai, T., Takagi, S., Suzuki, R., Nakajima, T., Hirai, K., Nomiyama, H., & Yoshie, O. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.39.27975 · Cited by 214
Liang, M., Mallari, C., Rosser, M., Ng, H. P., May, K., Monahan, S., Bauman, J. G., Islam, I., Ghannam, A., Buckman, B., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001222200 · Cited by 206
CCL2 Blockade Augments Cancer Immunotherapy
Fridlender, Z. G., Buchlis, G., Kapoor, V., Cheng, G., Sun, J., Singhal, S., Crisanti, M. C., Wang, L.-C. S., Heitjan, D., Snyder, L. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2326 · Cited by 193
Li, Q., Shi, L., Gui, B., Yu, W., Wang, J., Zhang, D., Han, X., Yao, Z., & Shang, Y. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1523 · Cited by 190
Twist1 Induces CCL2 and Recruits Macrophages to Promote Angiogenesis
Low-Marchelli, J. M., Ardi, V. C., Vizcarra, E. A., van Rooijen, N., Quigley, J. P., & Yang, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-0653 · Cited by 190
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy
Zhu, X., Fujita, M., Snyder, L. A., & Okada, H. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0473-5 · Cited by 189
Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5
Ogilvie, P., Bardi, G., Clark-Lewis, I., Baggiolini, M., & Uguccioni, M. (2001) · Blood · doi:10.1182/blood.v97.7.1920 · Cited by 187
Tumor‐stromal crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of CCL7
Jung, D., Che, Z. M., Kim, J., Kim, K., Kim, K., Williams, D., & Kim, J. (2010) · International Journal of Cancer · doi:10.1002/ijc.25060 · Cited by 186
Proteolytic Activation of Alternative CCR1 Ligands in Inflammation
Berahovich, R. D., Miao, Z., Wang, Y., Premack, B., Howard, M. C., & Schall, T. J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.7341 · Cited by 181
Kitamura, T., Fujishita, T., Loetscher, P., Revesz, L., Hashida, H., Kizaka-Kondoh, S., Aoki, M., & Taketo, M. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002372107 · Cited by 178
Stellato, C., Collins, P., Ponath, P. D., Soler, D., Newman, W., La Rosa, G., Li, H., White, J., Schwiebert, L. M., Bickel, C., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119257 · Cited by 177
Lança, T., Costa, M. F., Gonçalves-Sousa, N., Rei, M., Grosso, A. R., Penido, C., & Silva-Santos, B. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300434 · Cited by 168
Monocyte Chemoattractant Protein-3 Is a Functional Ligand for CC Chemokine Receptors 1 and 2B
Combadiere, C., Ahuja, S. K., Van Damme, J., Tiffany, H. L., Gao, J.-L., & Murphy, P. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.50.29671 · Cited by 166
Zhang, X., Chen, L., Dang, W.-Q., Cao, M.-F., Xiao, J.-F., Lv, S.-Q., Jiang, W.-J., Yao, X.-H., Lu, H.-M., Miao, J.-Y., et al. (2020) · Laboratory Investigation · doi:10.1038/s41374-019-0345-3 · Cited by 163
Doi, T., Muro, K., Ishii, H., Kato, T., Tsushima, T., Takenoyama, M., Oizumi, S., Gemmoto, K., Suna, H., Enokitani, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1090 · Cited by 161
White, J. R., Imburgia, C., Dul, E., Appelbaum, E., O'Donnell, K., O'Shannessy, D. J., Brawner, M., Fornwald, J., Adamou, J., Elshourbagy, N. A., et al. (1997) · Journal of Leukocyte Biology · doi:10.1002/jlb.62.5.667 · Cited by 160
Eosinophils in Cancer: Favourable or Unfavourable?
Sakkal, S., Miller, S., Apostolopoulos, V., & Nurgali, K. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160119094313 · Cited by 160
Koide, N., Nishio, A., Sato, T., Sugiyama, A., & Miyagawa, S.-I. (2004) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.30733.x · Cited by 158
Higashino, N., Koma, Y.-I., Hosono, M., Takase, N., Okamoto, M., Kodaira, H., Nishio, M., Shigeoka, M., Kakeji, Y., & Yokozaki, H. (2019) · Laboratory Investigation · doi:10.1038/s41374-018-0185-6 · Cited by 158
Tumor‐associated fibroblasts recruit blood monocytes into tumor tissue
Silzle, T., Kreutz, M. P., Dobler, M. A., Brockhoff, G., Knuechel, R., & Kunz‐Schughart, L. A. (2003) · European Journal of Immunology · doi:10.1002/eji.200323057 · Cited by 155
Mondini, M., Loyher, P.-L., Hamon, P., de Thoré, M. G., Laviron, M., Berthelot, K., Clémenson, C., Salomon, B. L., Combadière, C., Deutsch, É., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0633 · Cited by 154
Ohta, M., Kitadai, Y., Tanaka, S., Yoshihara, M., Yasui, W., Mukaida, N., Haruma, K., & Chayama, K. (2002) · International Journal of Cancer · doi:10.1002/ijc.10705 · Cited by 153
A Destructive Cascade Mediated by CCL2 Facilitates Prostate Cancer Growth in Bone
Li, X., Loberg, R. D., Liao, J., Chi, Y., Snyder, L. A., Pienta, K. J., & McCauley, L. K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2164 · Cited by 153
Fridlender, Z. G., Kapoor, V., Buchlis, G., Cheng, G., Sun, J., Wang, L. S., Singhal, S. K., Snyder, L. A., & Albelda, S. Μ. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0080oc · Cited by 151
Liu, L., Zhang, Z., Zheng, B., Shi, Y., Duan, M., Ma, L., Wang, Z., Dong, L., Dong, P., Shi, J.-Y., et al. (2018) · Hepatology · doi:10.1002/hep.30134 · Cited by 147
Tumour Tissue Microenvironment Can Inhibit Dendritic Cell Maturation in Colorectal Cancer
Michielsen, A. J., Hogan, A. E., Marry, J., Tosetto, M., Cox, F., Hyland, J. M., Sheahan, K. D., O’Donoghue, D. P., Mulcahy, H. E., Ryan, E. J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027944 · Cited by 146
Chen, X.-J., Deng, Y.-R., Wang, Z., Wei, W.-F., Zhou, C.-F., Zhang, Y., Yan, R.-M., Liang, L.-J., Zhong, M., Li, L., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1748-1 · Cited by 145
Inamoto, S., Itatani, Y., Yamamoto, T. S., Minamiguchi, S., Hirai, H., Iwamoto, M., Hasegawa, S., Taketo, M. M., Sakai, Y., & Kawada, K. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0726 · Cited by 140
Provost, V., Larose, M.-C., Langlois, A., Rola‐Pleszczynski, M., Flamand, N., & Laviolette, M. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0212074 · Cited by 138
Teng, K., Han, J., Zhang, X., Hsu, S., He, S., Wani, N. A., Barajas, J. M., Snyder, L. A., Frankel, W. L., Caligiuri, M. A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0124 · Cited by 138
Monocyte Chemotactic Protein-2 (MCP-2) Uses CCR1 AND CCR2B as Its Functional Receptors
Gong, X., Gong, W., Kuhns, D. B., Ben‐Baruch, A., Howard, O. M. Z., & Wang, J. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.18.11682 · Cited by 136
CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma
Gu, Y., Li, X., Bi, Y., Zheng, Y., Wang, J., Li, X., Huang, Z., Chen, L., Huang, Y., & Huang, Y. (2020) · Aging · doi:10.18632/aging.102656 · Cited by 133
Desai, S., Kumar, A., Laskar, S. S., & Pandey, B. N. (2012) · Cytokine · doi:10.1016/j.cyto.2012.08.022 · Cited by 132
Detheux, M., Ständker, L., Vakili, J., Münch, J., Forssmann, U., Adermann, K., Pöhlmann, S., Vassart, G., Kirchhoff, F., Parmentier, M., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.10.1501 · Cited by 132
HCC-1, a novel chemokine from human plasma.
Schulz‐Knappe, P., Mägert, H., Dewald, B., Meyer, M., Cetin, Y., Kubbies, M., Tomeczkowski, J., Kirchhoff, K., Raida, M., Adermann, K., et al. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.1.295 · Cited by 131
Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers
Moisan, F., Francisco, E. B., Brozović, A., Durán, G. E., Wang, Y. C., Chaturvedi, S., Seetharam, S., Snyder, L. A., Doshi, P. D., & Sikic, B. I. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.03.016 · Cited by 130
Kuroda, T., Kitadai, Y., Tanaka, S., Yang, X., Mukaida, N., Yoshihara, M., & Chayama, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0798 · Cited by 129
Wang, N., Docherty, F., Brown, H. K., Reeves, K. J., Fowles, A. C. M., Ottewell, P. D., Dear, T. N., Holen, I., Croucher, P. I., & Eaton, C. L. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2300 · Cited by 124
Fang, W. B., Yao, M., Brummer, G., Acevedo, D., Alhakamy, N. A., Berkland, C. J., & Cheng, N. (2016) · Oncotarget · doi:10.18632/oncotarget.9885 · Cited by 124
Dutta, P., Sarkissyan, M., Paico, K., Wu, Y., & Vadgama, J. V. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4760-8 · Cited by 124
Bélarbi, K., Jopson, T. D., Arellano, C., Fike, J. R., & Rosi, S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2989 · Cited by 123
Youn, B., Zhang, S., Lee, E. K., Park, D. H., Broxmeyer, H. E., Murphy, P. M., Locati, M., Pease, J. E., Kim, K. K., Antol, K., et al. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.11.5201 · Cited by 121
Fioretti, F., FRADELIZI, D., Stoppacciaro, A., Ramponi, S., Ruco, L., Minty, A. J., Sozzani, S., Garlanda, C., Vecchi, A., & Mantovani, A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.1.342 · Cited by 121
Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes
Ogilvie, P., Paoletti, S., Clark‐Lewis, I., & Uguccioni, M. (2003) · Blood · doi:10.1182/blood-2002-09-2773 · Cited by 119
Cancer-Associated Fibroblasts Promote Proliferation of Endometrial Cancer Cells
Subramaniam, K. S., Tham, S. T., Mohamed, Z., Woo, Y. L., Adenan, N. A. M., & Chung, I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068923 · Cited by 118
Krishnan, V., Tallapragada, S., Schaar, B. T., Kamat, K., Chanana, A. M., Zhang, Y., Patel, S. A., Parkash, V., Rinker-Schaeffer, C. W., Folkins, A. K., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01246-z · Cited by 117
Loyher, P.-L., Rochefort, J., de Chanville, C. B., Hamon, P., Lescaille, G., Bertolus, C., Guillot‐Delost, M., Krummel, M. F., Lemoine, F. M., Combadière, C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0984 · Cited by 116
Halvorsen, E. C., Hamilton, M. J., Young, A., Wadsworth, B. J., LePard, N. E., Lee, H. N., Firmino, N. S., Collier, J. L., & Bennewith, K. L. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1150398 · Cited by 115
Qian, D. Z., Rademacher, B. L. S., Pittsenbarger, J., Huang, C., Myrthue, A., Higano, C. S., Garzotto, M. G., Nelson, P. S., & Beer, T. M. (2009) · The Prostate · doi:10.1002/pros.21077 · Cited by 114
Eotaxin-3/CC Chemokine Ligand 26 Is a Functional Ligand for CX3CR1
Nakayama, T., Watanabe, Y., Oiso, N., Higuchi, T., Shigeta, A., Mizuguchi, N., Katou, F., Hashimoto, K., Kawada, A., & Yoshie, O. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904126 · Cited by 114
Regulation of chemokine activity by posttranslational modification
Mortier, A., Damme, J. V., & Proost, P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.08.006 · Cited by 112
Bartneck, M., Schrammen, P. L., Möckel, D., Govaere, O., Liepelt, A., Krenkel, O., Ergen, C., McCain, M. V., Eulberg, D., Luedde, T., et al. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.10.007 · Cited by 112
Pausch, T. M., Aue, E., Wirsik, N. M., Valls, A. F., Shen, Y., Radhakrishnan, P., Hackert, T., Schneider, M. A., & Schmidt, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-62416-x · Cited by 109
A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer
Berlato, C., Khan, M. N., Schioppa, T., Thompson, R. D., Maniati, E., Montfort, A., Jangani, M., Canosa, M., Kulbe, H., Hagemann, U. B., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci82976 · Cited by 108
Chen, W., Yang, C., Wang, S., Shi, D., Zhang, C., Lin, X., & Xiong, B. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s198126 · Cited by 107
Xie, F., Liu, L.-B., Shang, W.-Q., Chang, K., Meng, Y., Mei, J., Yu, J., Li, D., & Li, M. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.04.029 · Cited by 106
Lin, Z., Chuang, Y.-H., & Chuang, W. (2012) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2012.02.001 · Cited by 106
Monocyte chemotactic protein-3.
Menten, P., Wuyts, A., & Damme, J. V. (2001) · PubMed · Cited by 105
Li, S., Lü, J., Chen, Y., Xiong, N., Li, L., Zhang, J., Yang, H., Wu, C., Zeng, H., & Liu, Y. (2016) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.106 · Cited by 105
Lee, Y. S., Kim, S.-Y., Hong, H. K., Hong, H. K., Lee, Y., Oh, B. Y., Lee, W. Y., & Cho, Y. B. (2016) · Oncotarget · doi:10.18632/oncotarget.9209 · Cited by 105
Maruyama, T., Kono, K., Izawa, S., Mizukami, Y., Kawaguchi, Y., Mimura, K., Watanabe, M., & Fujii, H. (2009) · Diseases of the Esophagus · doi:10.1111/j.1442-2050.2009.01029.x · Cited by 103
Monocyte Chemoattractant Protein (MCP)-4 Expression in the Airways of Patients with Asthma
Lamkhioued, B., García-Zepeda, E. A., Abi-Younes, S., Nakamura, H., Jedrzkiewicz, S., Wagner, L., RENZI, P. M., Allakhverdi, Z., Lilly, C. M., Hamid, Q. A., et al. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.2.9901080 · Cited by 103
Eotaxin Is a Potent Chemotaxin for Human Basophils
Yamada, H., Hirai, K., Miyamasu, M., Iikura, M., Misaki, Y., Shoji, S., Takaishi, T., Kasahara, T., Morita, Y., & Ito, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6100 · Cited by 102
Mohamed, M. M., Elghonaimy, E. A., Nouh, M. A., Schneider, R. J., Sloane, B. F., & El‐Shinawi, M. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.11.015 · Cited by 101
CCL16 activates an angiogenic program in vascular endothelial cells
Strasly, M. (2003) · Blood · doi:10.1182/blood-2003-05-1387 · Cited by 101
Hwang, J.-S., Son, K., Kim, C. W., et al. (2005) · Cytokine · doi:10.1016/j.cyto.2005.01.018 · Cited by 100
Retinoblastoma Inactivation Induces a Protumoral Microenvironment via Enhanced CCL2 Secretion
Li, F., Kitajima, S., Kohno, S., Yoshida, A., Tange, S., Sasaki, S., Okada, N., Nishimoto, Y., Muranaka, H., Nagatani, N., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3604 · Cited by 100
Dagouassat, M., Suffee, N., Hlawaty, H., Haddad, O., Charni, F., Laguillier, C., Vassy, R., Martin, L., Schischmanoff, P. O., Gattegno, L., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24800 · Cited by 99
Nakamura, E. S., Koizumi, K., Kobayashi, M., Saitoh, Y., Arita, Y., Nakayama, T., Sakurai, H., Yoshie, O., & Saiki, I. (2006) · Clinical & Experimental Metastasis · doi:10.1007/s10585-006-9006-1 · Cited by 99
Up-Regulation of Functional Chemokine Receptor CCR3 in Human Renal Cell Carcinoma
Jöhrer, K., Zelle‐Rieser, C., Perathoner, A., Moser, P. L., Hager, M., Ramoner, R. E., Gander, H., Höltl, L., Bartsch, G. H., Greil, R., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0405 · Cited by 98
Eotaxin-3/CCL26 Is a Natural Antagonist for CC Chemokine Receptors 1 and 5
Petkovic, V., Moghini, C., Paoletti, S., Uguccioni, M., & Gerber, B. O. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309283200 · Cited by 97
Li, Y.-Q., Liu, F., Zhang, X.-M., Guo, X.-J., Ren, M.-J., & Fu, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076379 · Cited by 97
Nomiyama, H., Hieshima, K., Nakayama, T., Sakaguchi, T., Fujisawa, R., Tanase, S., Nishiura, H., Matsuno, K., Takamori, H., Tabira, Y., et al. (2001) · International Immunology · doi:10.1093/intimm/13.8.1021 · Cited by 97
Shen, S., Zhang, Y., Chen, K., Luo, Y., & Wang, J. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00997 · Cited by 97
Berkhout, T. A., Sarau, H. M., Moores, K., White, J. R., Elshourbagy, N. A., Appelbaum, E. R., Brawner, T. J., Reape, M., Makwana, J., Foley, J. J., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.26.16404 · Cited by 96
CCL22 Recruits CD4-positive CD25-positive Regulatory T Cells into Malignant Pleural Effusion
Qin, X., Shi, H., Deng, J., Liang, Q.-L., Jiang, J., & Ye, Z. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2641 · Cited by 96
HCC-2, a human chemokine: Gene structure, expression pattern, and biological activity
Pardigol, A., Forssmann, U., Zucht, H., Loetscher, P., Schulz‐Knappe, P., Baggiolini, M., Forssmann, W., & Mägert, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6308 · Cited by 95
CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer
Maeda, S., Murakami, K., Inoue, A., Yonezawa, T., & Matsuki, N. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0751 · Cited by 95
Yamamoto, T. S., Kawada, K., Itatani, Y., Inamoto, S., Okamura, R., Iwamoto, M., Miyamoto, E., Chen-Yoshikawa, T. F., Hirai, H., Hasegawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0520 · Cited by 91
Youn, B., Zhang, S. M., Broxmeyer, H. E., Cooper, S. H., Antol, K., Fraser, M. J., & Kwon, B. S. (1998) · Blood · doi:10.1182/blood.v91.9.3118 · Cited by 89
A CCL8 gradient drives breast cancer cell dissemination
Farmaki, E., Chatzistamou, I., Kaza, V., & Kiaris, H. (2016) · Oncogene · doi:10.1038/onc.2016.161 · Cited by 89
Vickman, R. E., Broman, M. M., Lanman, N. A., Franco, O. E., Sudyanti, P. A. G., Ni, Y., Ji, Y., Helfand, B. T., Petkewicz, J., Paterakos, M. C., et al. (2020) · The Prostate · doi:10.1002/pros.23929 · Cited by 88
Rapp, M., Grassmann, S. A., Chaloupka, M., Layritz, P., Krüger, S., Ormanns, S., Rataj, F., Janssen, K., Endres, S., Anz, D., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1105428 · Cited by 87
Giovarelli, M., Cappello, P., Forni, G., Salcedo, T. W., Moore, P. A., LeFleur, D. W., Nardelli, B., Carlo, E. D., Lollini, P., Ruben, S. M., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.6.3200 · Cited by 86
Chemokine Decoy Receptor D6 Plays a Negative Role in Human Breast Cancer
Wu, F.-Y., Ou, Z.-L., Feng, L.-Y., Luo, J.-M., Wang, L.-P., Shen, Z., & Shao, Z.-M. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2108 · Cited by 86
Ruffing, N., Sullivan, N. J., Sharmeen, L., Sodroski, J., & Wu, L. (1998) · Cellular Immunology · doi:10.1006/cimm.1998.1379 · Cited by 85
Transactivation of MCP‐1/CCL2 by β‐catenin/TCF‐4 in human breast cancer cells
Mestdagt, M., Polette, M., Butticè, G., Noël, A., Ueda, A., Foidart, J., & Gilles, C. (2005) · International Journal of Cancer · doi:10.1002/ijc.21291 · Cited by 85
Thomas, J. K., Mir, H., Kapur, N., Bae, S., & Singh, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-40514-9 · Cited by 85
Li, Y., Zheng, Y., Li, T., Wang, Q., Qian, J., Lu, Y., Zhang, M., Bi, E., Yang, M., Reu, F. J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4523 · Cited by 84
Lapteva, N., Aldrich, M. B., Weksberg, D. C., Rollins, L. A., Goltsova, T., Chen, S. Y., & Huang, X. F. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318193d31e · Cited by 84
The Chemokine (CCL2–CCR2) Signaling Axis Mediates Perineural Invasion
He, S., He, S., Chen, C., Deborde, S., Bakst, R. L., Chernichenko, N., McNamara, W. F., Lee, S. Y., Barajas, F., Yu, Z., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0303 · Cited by 84
Schwann Cell-Derived CCL2 Promotes the Perineural Invasion of Cervical Cancer
Huang, T., Fan, Q., Wang, Y., Cui, Y., Wang, Z., Yang, L., Sun, X. G., & Wang, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00019 · Cited by 83
Hannan, N. J., & Salamonsen, L. A. (2008) · Biology of Reproduction · doi:10.1095/biolreprod.107.066480 · Cited by 82
Tsujikawa, T., Yaguchi, T., Ohmura, G., Ohta, S., Kobayashi, A., Kawamura, N., Fujita, T., Nakano, H., Shimada, T., Takahashi, T., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27966 · Cited by 80
Angiogenic activity of human CC chemokine CCL15 in vitro and in vivo
Hwang, J.-S., Kim, C. W., Son, K., Han, K., Lee, K. H., Kleinman, H. K., Ko, J., Na, D. S., Kwon, B. S., Gho, Y. S., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.06.023 · Cited by 79
Atypical chemokine receptors in cancer: friends or foes?
Massara, M., Bonavita, O., Mantovani, A., Locati, M., & Bonecchi, R. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3mr0915-431rr · Cited by 79
Increasing the efficacy of radiotherapy by modulating the CCR2/CCR5 chemokine axes
Connolly, K. A., Belt, B. A., Figueroa, N. M., Murthy, A., Patel, A. P., Kim, M., Lord, E. M., Linehan, D. C., & Gerber, S. A. (2016) · Oncotarget · doi:10.18632/oncotarget.13287 · Cited by 79
Monocyte Chemotactic Protein 1 Promotes Lung Cancer–Induced Bone Resorptive Lesions In Vivo
Cai, Z. Y., Chen, Q., Chen, J., Lü, Y., Xiao, G., Wu, Z., Zhou, Q., & Zhang, J. (2009) · Neoplasia · doi:10.1593/neo.81282 · Cited by 78
ZHU, F., Liu, P., Jun, L., & Zhang, Y. (2014) · Oncology Reports · doi:10.3892/or.2014.3060 · Cited by 78
Zhu, F., Li, X., Chen, S., Zeng, Q., Zhao, Y., & Luo, F. (2016) · Medical Oncology · doi:10.1007/s12032-016-0729-9 · Cited by 78
CCR4 is a determinant of melanoma brain metastasis
Klein, A., Sagi‐Assif, O., Meshel, T., Telerman, A., Izraely, S., Ben‐Menachem, S., Bayry, J., Marzese, D. M., Ohe, S., Hoon, D. S. �., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16076 · Cited by 78
Cho, H. R., Kumari, N., Vu, H. T., Kim, H., Park, C., & Choi, S. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-47438-4 · Cited by 78
Ishida, T., Utsunomiya, A., Jo, T., Yamamoto, K., Kato, K., Yoshida, S., Takemoto, S., Suzushima, H., Kobayashi, Y., Imaizumi, Y., et al. (2017) · Cancer Science · doi:10.1111/cas.13343 · Cited by 76
The chemokine receptors ACKR2 and CCR2 reciprocally regulate lymphatic vessel density
Lee, K. M., Danuser, R., Stein, J. V., Graham, D., Nibbs, R. J. B., & Graham, G. J. (2014) · The EMBO Journal · doi:10.15252/embj.201488887 · Cited by 74
Chemokines mediate mesenchymal stem cell migration toward gliomas in vitro
Xu (2010) · Oncology Reports · doi:10.3892/or_00000796 · Cited by 73
Nakayama, T., Kato, Y., Hieshima, K., Nagakubo, D., Kunori, Y., Fujisawa, T., & Yoshie, O. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.3.2078 · Cited by 73
Lan, Q., Wei, L., Zeng, Y., Liu, L., Li, S., Jin, S., Zhang, Y., Luo, X., Xu, H., Lin, X., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0507 · Cited by 73
Starr, A. E., Dufour, A., Maier, J., & Overall, C. M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.314609 · Cited by 72
Yao, M., Fang, W. B., Smart, C., Hu, Q., Huang, S., Alvarez, N. S., Fields, P. E., & Cheng, N. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0750 · Cited by 72
Wu, H., Zhang, X., Han, D., Cao, J., & Tian, J. (2020) · PeerJ · doi:10.7717/peerj.8721 · Cited by 72
Omland, S. H., Wettergren, E. E., Mollerup, S., Asplund, M., Mourier, T., Hansen, A. J., & Gniadecki, R. (2017) · BMC Cancer · doi:10.1186/s12885-017-3663-0 · Cited by 71
Zhang, W., Chen, L., Ma, K., Zhao, Y., Liu, X., Wang, Y., Liu, M., Liang, S., Zhu, H., & Xu, N. (2016) · Oncotarget · doi:10.18632/oncotarget.12207 · Cited by 70
Absence of CCL2 is sufficient to restore hippocampal neurogenesis following cranial irradiation
Lee, S. W., Haditsch, U., Cord, B. J., Guzman, R. G., Kim, S., Böttcher, C., Priller, J., Ormerod, B. K., & Palmer, T. D. (2012) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.09.010 · Cited by 67
Li, J., Hu, P., Khawli, L. A., & Epstein, A. L. (2003) · PubMed · Cited by 66
Guo, J., Wang, B., Zhang, M., Chen, T., Yu, Y., Régulier, E., Homann, H., Qin, Z., Dw, J., & Cao, X. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301688 · Cited by 66
Nardelli, B., Tiffany, H. L., Bong, G. W., Yourey, P. A., Morahan, D. K., Li, Y., Murphy, P. M., & Alderson, R. F. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.1.435 · Cited by 65
Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients
Wertel, I., Surówka, J., Polak, G., Barczyński, B., Bednarek, W., Jakubowicz-Gil, J., Bojarska-Junak, A. A., & Kotarski, J. (2015) · Tumor Biology · doi:10.1007/s13277-015-3133-8 · Cited by 65
Lü, Y., Xiao, G., Galson, D. L., Nishio, Y., Mizokami, A., Keller, E. T., Yao, Z., & Zhang, J. (2007) · International Journal of Cancer · doi:10.1002/ijc.22704 · Cited by 65
Magge, S. N., Malik, S. Z., Royo, N. C., Chen, H. I., Yu, L., Snyder, E. Y., O’Rourke, D. M., & Watson, D. J. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.21983 · Cited by 65
Eotaxin-2 and Colorectal Cancer: A Potential Target for Immune Therapy
Cheadle, E. J., Riyad, K., Subar, D. A., Rothwell, D. G., Ashton, G., Batha, H., Sherlock, D., Hawkins, R. E., & Gilham, D. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1145 · Cited by 65
Coulin, F., Power, C. A., Alouani, S., Peitsch, M. C., Schroeder, J. A., Moshizuki, M., Clark‐Lewis, I., & Wells, T. N. C. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00507.x · Cited by 64
Eosinophils in Colorectal Neoplasms Associated with Expression of CCL11 and CCL24
Cho, H., Lim, S., Won, K. Y., Bae, G. E., Kim, G. Y., Min, J. W., & Noh, B. (2015) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2015.10.16 · Cited by 64
Lai, J., Zhu, Y., Ruan, M., Chen, L., & Zhang, Q. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02857 · Cited by 64
Tsou, C.-L., Gladue, R. P., Carroll, L. A., Paradis, T., Boyd, J. G., Nelson, R. T., Neote, K. S., & Charo, I. F. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.3.603 · Cited by 63
Votta, B. J., White, J. R., Dodds, R. A., James, I. E., Connor, J. R., ELIZABETH, E., Lee-Rykaczewski, Eichman, C. F., Kumar, S., Lark, M. W., et al. (2000) · Journal of Cellular Physiology · Cited by 63
Wetzel, K., Menten, P., Opd�nakker, G., Damme, J. V., Gröne, H., Giese, N. A., Vecchi, A., Sozzani, S., Cornelis, J. J., Rommelaere, J., et al. (2001) · The Journal of Gene Medicine · doi:10.1002/jgm.191 · Cited by 63
Nakasone, Y., Fujimoto, M., Matsushita, T., Hamaguchi, Y., Huu, D. L., Yanaba, M., Sato, S., Takehara, K., & Hasegawa, M. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.09.005 · Cited by 63
Varney, M. L., Olsen, K. J., Mosley, R. L., & Singh, R. K. (2005) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2005.25.674 · Cited by 63
Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia
Çelik, H., Lindblad, K. E., Popescu, B. O., Gui, G., Goswami, M., Valdez, J., DeStefano, C. B., Lai, C., Thompson, J., Ghannam, J. Y., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001124 · Cited by 63
Liu, W., Wei, X., Li, L., Wu, X., Yan, J., Yang, H. L., & Song, F. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.034 · Cited by 62
Lorena, S. C. M., Oliveira, D. T., Dorta, R. G., Landman, G., & Kowalski, L. P. (2003) · Oral Diseases · doi:10.1034/j.1601-0825.2003.00958.x · Cited by 61
MiR-345-5p functions as a tumor suppressor in pancreatic cancer by directly targeting CCL8
Mou, T., Xie, F., Zhong, P., Hua, H., Lai, L., Yang, Q., & Wang, J. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.121 · Cited by 61
Jin, L., Liu, W., Tian, M., Jiang, X., Wang, H., Zhou, P., Ding, Z., Peng, Y., Dai, Z., Qiu, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14095 · Cited by 60
CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells
Natsagdorj, A., Izumi, K., Hiratsuka, K., Machioka, K., Iwamoto, H., Naito, R., Makino, T., Kadomoto, S., Shigehara, K., Kadono, Y., et al. (2018) · Cancer Science · doi:10.1111/cas.13876 · Cited by 58
Yin, X., Han, S., Song, C., Zou, H., Wei, Z., Xu, W., Ran, J., Tang, C., Wang, Y., Cai, Y., et al. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00446-y · Cited by 58
Cohen, E. E. W., Pishvaian, M. J., Shepard, D. R., Wang, D., Weiss, J., Johnson, M. L., Chung, C. H., Chen, Y., Huang, B., Davis, C. B., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0815-6 · Cited by 57
Kimura, S., Nanbu, U., Noguchi, H., Harada, Y., Kumamoto, K., Sasaguri, Y., & Nakayama, T. (2019) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12885 · Cited by 56
Wang, Z., Yang, Y., Cui, Y., Wang, C., Lai, Z., Li, Y., Zhang, W., Mustonen, H. K., Puolakkainen, P. A., Ye, Y., et al. (2020) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2020.01.09 · Cited by 56
CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac
van Golen, K. L., Ying, C., Sequeira, L., Dubyk, C. W., Reisenberger, T., Chinnaiyan, A. M., Pienta, K. J., & Loberg, R. D. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21652 · Cited by 55
Kanagawa, N., Niwa, M., Hatanaka, Y., Tani, Y., Nakagawa, S., Fujita, T., Yamamoto, A., & Okada, N. (2007) · International Journal of Cancer · doi:10.1002/ijc.22908 · Cited by 54
Cited by
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Macrophage Polarity and Disease Control
Kadomoto, S., Izumi, K., & Mizokami, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010144 · Cited by 318
Glioblastoma at the crossroads: current understanding and future therapeutic horizons
Singh, S., Dey, D., Barik, D., Mohapatra, I., Kim, S., Sharma, M., Prasad, S., Wang, P., Singh, A., & Singh, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02299-4 · Cited by 287
Wang, J., Zhou, X., Yu, P., Yao, J., Guo, P., Xu, Q., Zhao, Y., Wang, G., Li, Q., Zhu, X., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00886-2 · Cited by 28
Metadata
- Authors
- Korbecki, J., Kojder, K., Simińska, D., Bohatyrewicz, R., Gutowska, I., Chlubek, D., & Baranowska-Bosiacka, I.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-11-09
- Volume
- 21
- Issue
- 21
- Pages
- 8412
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3106021040
- Cited by
- 465
- References
- 259
- FWCI
- 16.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.